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A novel receptor for Apo2L/TRAIL contains a truncated death
domain
S.A. Marsters*, J.P. Sheridan*, R.M. Pitti*, A. Huang†, M. Skubatch*, 
D. Baldwin†, J. Yuan†, A. Gurney†, A.D. Goddard†, P. Godowski† and 
A. Ashkenazi*
Apo2 ligand (Apo2L [1], also called TRAIL for tumor
necrosis factor (TNF)-related apoptosis-inducing ligand
[2]) belongs to the TNF family and activates apoptosis in
tumor cells. Three closely related receptors bind Apo2L:
DR4 and DR5, which contain cytoplasmic death domains
and signal apoptosis, and DcR1, a decoy receptor that
lacks a cytoplasmic tail and inhibits Apo2L function [3–5].
By cross-hybridization with DcR1, we have identified a
fourth Apo2L receptor, which contains a cytoplasmic
region with a truncated death domain. We subsequently
named this protein decoy receptor 2 (DcR2). The DcR2
gene mapped to human chromosome 8p21, as did the
genes encoding DR4, DR5 and DcR1. A single DcR2
mRNA transcript showed a unique expression pattern in
human tissues and was particularly abundant in fetal
liver and adult testis. Upon overexpression, DcR2 did not
activate apoptosis or nuclear factor-kB; however, it
substantially reduced cellular sensitivity to Apo2L-
induced apoptosis. These results suggest that DcR2
functions as an inhibitory Apo2L receptor.
Addresses: *Department of Molecular Oncology, Genentech Inc., 
1 DNA Way, South San Francisco, California 94080-4918, USA.
†Department of Molecular Biology, Genentech Inc., 1 DNA Way, South
San Francisco, California 94080-4918, USA.
Correspondence: Avi Ashkenazi
E-mail: aa@gene.com
Received: 26 August 1997
Revised: 6 October 1997
Accepted: 6 October 1997
Current Biology 1997, 7:1003–1006
http://biomednet.com/elecref/0960982200701003
© Current Biology Ltd ISSN 0960-9822
Results and discussion
We screened a human fetal lung complementary DNA
(cDNA) library by hybridization to a probe based on the
extracellular domain (ECD) of DcR1 [4]. We identified
two virtually identical cDNA clones encoding a previously
undescribed receptor, which we designated DcR2. The
clones predict a 386-residue polypeptide precursor
(Figure 1a). The clones have a single base difference in
codon 310, encoding either a serine residue (TCG) or a
leucine residue (TTG). Hydropathy analysis (data not
shown) suggests that DcR2 has a type I transmembrane
protein topology (Figure 1a). The ECD contains two
cysteine-rich regions (Figure 1b), and shows remarkably
greater identity to the ECDs of DR4 (55%), DR5 (56%) or
DcR1 (67%) than to those of tumor necrosis factor recep-
tor-1 (TNFR1) (26%), Fas/Apo1 (CD95) (27%) [6] or
Apo3/DR3 (19%) [7–10] (Figure 1b). The intracellular
domain (ICD) also shows greater homology to DR4 (60%)
or DR5 (49%) than to TNFR1 (18%), CD95 (14%) or
Apo3/DR3 (10%) (Figure 1c). This region contains an
apparently truncated ‘death domain’, which is about one-
third of the length of the death domains found in other
TNFR superfamily members and in associated adaptor
proteins [6]. Notably, five out of six death-domain
residues that are essential for signaling by TNFR1 [11],
including the position that corresponds to the CD95-inac-
tivating mouse lpr mutation [6], are identical or similar in
DR4 and DR5, but are absent in DcR2 (Figure 1c). PCR
analysis of several cDNA libraries with primers that flank
the truncated DcR2 death domain revealed a single
product, which matched the corresponding region of our
two clones in size and in sequence (data not shown), sug-
gesting that there is one predominant splice form of DcR2.
We investigated the chromosomal location of the human
DcR2 gene and its close relatives by radiation-hybrid
analysis (Research Genetics) with PCR primers based on
the unique 3′ untranslated region of each receptor. DcR2
was linked to marker SHGC33989 (LOD = 7.2); DR4 to
D8S2127 (LOD = 13.0); DR5 to DS481 (LOD = 11.1); and
DcR1 to WI6536 (LOD > 3.0). Each of the first three
markers is linked to D8S2055, which maps physically to
chromosome 8p21, and WI6536 is linked to D8S298,
which maps also to 8p21.
Next, we analyzed the expression of DcR2 mRNA in
human tissues (Figure 2). We detected only one mRNA
transcript of approximately 4 kilobases (kb), consistent
with a single splice form of DcR2. The transcript was
expressed in fetal kidney, lung and particularly liver, and
in many adult tissues, especially testis and kidney. This
expression pattern differs from that of DR4, DR5 or DcR1
[3–5]: DR4 is particularly abundant in peripheral blood
leukocytes (PBL) and spleen, DR5 in ovary, liver and
lung, and DcR1 in PBL, spleen, lung and placenta.
To investigate whether DcR2 binds to Apo2L, we gener-
ated IgG fusion proteins (immunoadhesins) based on the
ECDs of DcR2 and other receptors. Immunoadhesins
based on DcR2 or DR5, but not those based on TNFR1,
co-precipitated radiolabeled Apo2L; this co-precipitation
was blocked by excess unlabeled Apo2L (Figure 3a). Bia-
core analysis demonstrated that the DcR2 immunoadhesin
bound to Apo2L, but not to TNF, lymphotoxin α or CD95
ligand (data not shown). Furthermore, DcR2, but not
TNFR1, immunoadhesin blocked the ability of Apo2L to
induce apoptosis in human HeLa cells (Figure 3b). These
results indicate that DcR2 is a specific receptor for Apo2L.
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Figure 1
DcR2       1  --MGLWGQSVPTASSARA--GRYPGARTASGTRPWLLDPKILKFVVFIVA

DR4       51  GRGALPTSMGQHGPSARARAGRAPGPRPAREASPRLRVHKTFKFV--VVG

DR5        1  --MEQRGQNAPAASGARKRHG--PGPREARGARPGLRVPKTLVLV--VVA

DcR1       1  ----------------------------------MARIPKTLKFVVVIVA



DcR2      47  VLLPVRVDSATIPRQDEVPQQTVAPQQQRRSLKEEECPAGSHRSEYTGAC

DR4       99  VLLQVVPSSAATIKLH---DQSIGTQQWEHSPLGELCPPGSHRSERPGAC

DR5       45  VLLLVSAESALITQQDLAPQQRAAPQQKRSSPSEGLCPPGHHISEDGRDC

DcR1      17  VLLPVLAYSATTARQEEVPQQTVAPQQQRHSFKGEECPAGSHRSEHTGAC



DcR2      97  NPCTEGVDYTIASNNLPSCLLCTVCKSGQTNKSSCTTTRDTVCQCEKGSF

DR4      146  NRCTEGVGYTNASNNLFACLPCTACKSDEEERSPCTTTRNTACQCKPGTF

DR5       95  ISCKYGQDYSTHWNDLLFCLRCTRCDSGEVELSPCTTTRNTVCQCEEGTF 

DcR1      67  NPCTEGVDYTNASNNEPSCFPCTVCKSDQKHKSSCTMTRDTVCQCKEG



DcR2     147  QDKNSPEHCRTCRTGCPRGHVKVSNCTPRSDIKCKNESAASSTGKTPAAE

DR4      196  RNDNSAEHCRKCSTGCPRGHVKVKDCTPWSDIECVHKESGNGHNIW----

DR5      145  REEDSPEHCRKCRTGCPRGHVKVGDCTPWSDIECVHKESGIIIGVTVAA-

DcR1     117  RNENSPEHCRKCSR-CPSGEVQVSNCTSWDDIQCVEEFGANAT------

     1 CCAACTGCAC CTCGGTTCTA TCGATTGAAT TCCCCGGGGA TCCTCTAGAG ATCCCTCGAC

    61 CTCGACCCAC GCGTCCGGAA CCTTTGCACG CGCACAAACT ACGGGGACGA TTTCTGATTG

   121 ATTTTTGGCG CTTTCGATCC ACCCTCCTCC CTTCTCATGG GACTTTGGGG ACAAAGCGTC

     1                                        M  G   L  W  G   Q  S  V



   181 CCGACCGCCT CGAGCGCTCG AGCAGGGCGC TATCCAGGAG CCAGGACAGC GTCGGGAACC

     9 P  T  A  S   S  A  R   A  G  R   Y  P  G  A   R  T  A   S  G  T



   241 AGACCATGGC TCCTGGACCC CAAGATCCTT AAGTTCGTCG TCTTCATCGT CGCGGTTCTG

    29 R  P  W  L   L  D  P   K  I  L   K  F  V  V   F  I  V   A  V  L



   301 CTGCCGGTCC GGGTTGACTC TGCCACCATC CCCCGGCAGG ACGAAGTTCC CCAGCAGACA

    49 L  P  V  R   V  D  S   A  T  I   P  R  Q  D   E  V  P   Q  Q  T



   361 GTGGCCCCAC AGCAACAGAG GCGCAGCCTC AAGGAGGAGG AGTGTCCAGC AGGATCTCAT

    69 V  A  P  Q   Q  Q  R   R  S  L   K  E  E  E   C  P  A   G  S  H



   421 AGATCAGAAT ATACTGGAGC CTGTAACCCG TGCACAGAGG GTGTGGATTA CACCATTGCT

    89 R  S  E  Y   T  G  A   C  N  P   C  T  E  G   V  D  Y   T  I  A



   481 TCCAACAATT TGCCTTCTTG CCTGCTATGT ACAGTTTGTA AATCAGGTCA AACAAATAAA

   109 S  N  N  L   P  S  C   L  L  C   T  V  C  K   S  G  Q   T  N  K



   541 AGTTCCTGTA CCACGACCAG AGACACCGTG TGTCAGTGTG AAAAAGGAAG CTTCCAGGAT

   129 S  S  C  T   T  T  R   D  T  V   C  Q  C  E   K  G  S   F  Q  D



   601 AAAAACTCCC CTGAGATGTG CCGGACGTGT AGAACAGGGT GTCCCAGAGG GATGGTCAAG

   149 K  N  S  P   E  M  C   R  T  C   R  T  G  C   P  R  G   M  V  K



   661 GTCAGTAATT GTACGCCCCG GAGTGACATC AAGTGCAAAA ATGAATCAGC TGCCAGTTCC

   169 V  S  N  C   T  P  R   S  D  I   K  C  K  N   E  S  A   A  S  S



   721 ACTGGGAAAA CCCCAGCAGC GGAGGAGACA GTGACCACCA TCCTGGGGAT GCTTGCCTCT

   189 T  G  K  T   P  A  A   E  E  T   V  T  T  I   L  G  M   L  A  S



   781 CCCTATCACT ACCTTATCAT CATAGTGGTT TTAGTCATCA TTTTAGCTGT GGTTGTGGTT

   209 P  Y  H  Y   L  I  I   I  V  V   L  V  I  I   L  A  V   V  V  V 



   841 GGCTTTTCAT GTCGGAAGAA ATTCATTTCT TACCTCAAAG GCATCTGCTC AGGTGGTGGA

   229 G  F  S  C   R  K  K   F  I  S   Y  L  K  G   I  C  S   G  G  G



   901 GGAGGTCCCG AACGTGTGCA CAGAGTCCTT TTCCGGCGGC GTTCATGTCC TTCACGAGTT

   249 G  G  P  E   R  V  H   R  V  L   F  R  R  R   S  C  P   S  R  V



   961 CCTGGGGCGG AGGACAATGC CCGCAACGAG ACCCTGAGTA ACAGATACTT GCAGCCCACC

   269 P  G  A  E   D  N  A   R  N  E   T  L  S  N   R  Y  L   Q  P  T



  1021 CAGGTCTCTG AGCAGGAAAT CCAAGGTCAG GAGCTGGCAG AGCTAACAGG TGTGACTGTA

   289 Q  V  S  E   Q  E  I   Q  G  Q   E  L  A  E   L  T  G   V  T  V



  1081 GAGTCGCCAG AGGAGCCACA GCGTCTGCTG GAACAGGCAG AAGCTGAAGG GTGTCAGAGG

   309 E  S  P  E   E  P  Q   R  L  L   E  Q  A  E   A  E  G   C  Q  R



  1141 AGGAGGCTGC TGGTTCCAGT GAATGACGCT GACTCCGCTG ACATCAGCAC CTTGCTGGAT

   329 R  R  L  L   V  P  V   N  D  A   D  S  A  D   I  S  T   L  L  D



  1201 GCCTCGGCAA CACTGGAAGA AGGACATGCA AAGGAAACAA TTCAGGACCA ACTGGTGGGC

   349 A  S  A  T   L  E  E   G  H  A   K  E  T  I   Q  D  Q   L  V  G



  1261 TCCGAAAAGC TCTTTTATGA AGAAGATGAG GCAGGCTCTG CTACGTCCTG CCTGTGAAAG

   369 S  E  K  L   F  Y  E   E  D  E   A  G  S  A   T  S  C   L   



  1321 AATCTCTTCA GGAAACCAGA GCTTCCCTCA TTTACCTTTT CTCCTACAAA GGGAAGCAGC

  1381 CTGGAAGAAA CAGTCCAGTA CTTGACCCAT GCCCCAACAA ACTCTACTAT CCAATATGGG

  1441 GCAGCTTACC AATGGTCCTA GAACTTTGTT AACGCACTTG GAGTAATTTT TATGAAATAC

  1501 TGCGTGTGAT AAGCAAACGG GAGAAATTTA TATCAGATTC TTGGCTGCAT AGTTATACGA

  1561 TTGTGTATTA AGGGTCGTTT TAGGCCACAT GCGGTGGCTC ATGCCTGTAA TCCCAGCACT

  1621 TTGATAGGCT GAGGCAGGTG GATTGCTTGA GCTCGGGAGT TTGAGACCAG CCTCATCAAC

  1681 ACAGTGAAAC TCCATCTCAA TTTAAAAAGA AAAAAAGTGG TTTTAGGATG TCATTCTTTG

  1741 CAGTTCTTCA TCATGAGACA AGTCTTTTTT TCTGCTTCTT ATATTGCAAG CTCCATCTCT
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(a) Nucleotide and predicted amino-acid sequence of human DcR2
(GenBank accession number 147230). Indicated are the putative
signal peptide as determined by amino-terminal sequence analysis of
DcR2–IgG (yellow), the transmembrane domain (magenta) and
potential N-linked glycosylation sites (red). Serine 310 of clone 35663
is replaced by a leucine in clone 35664. (b) Extracellular sequence
alignment. Highlighted are conserved amino acids (blue), and the
cysteines of each cysteine-rich domain, CRD (red). (c) Cytoplasmic
sequence alignment. Conserved amino acids are in blue. Red indicates
positions that are important for death signaling by TNFR1 [11] and
CD95 [6]. DD, death domain. (d) Domain organization of Apo2L
receptors. S, signal sequence; CRD1, CRD2, cysteine-rich domains;
TM, transmembrane domain; TD, truncated death domain; DD, death
domain. In DcR1, 1–5 are pseudorepeats of 15 amino acids. The
topology of DR4 is based on [3].
Overexpression of death-domain-containing receptors
such as DR4 or DR5 leads to activation of apoptosis and of
nuclear factor-κB (NF-κB) [3–5]. HeLa cells transfected
with either DcR2 clone showed no increase in cell death,
whereas cells transfected with DR4 or DR5 showed
higher levels of apoptosis (Figure 4a). Similarly, transfec-
tion of human 293 cells with DcR2 did not increase NF-
κB activity, whereas DR4 or DR5 caused NF-κB
activation (Figure 4b). These results suggest that the trun-
cated death domain of DcR2 is not functional.
We tested the effect of DcR2 transfection on the induc-
tion of apoptosis by Apo2L. DcR2-transfected cells were
substantially less sensitive than control vector-transfected
cells to Apo2L-induced apoptosis (Figure 4c), but showed
little difference in sensitivity to induction of apoptosis
through CD95 (Figure 4d). These data support the con-
clusion that DcR2 does not signal cell death and demon-
strate that high levels of DcR2 can specifically inhibit the
cytotoxic action of Apo2L. Deletion of the ICD of DcR2
did not affect its activity (Figure 4c), indicating that this
region is not critical for the inhibition of Apo2L.
Although there is evidence that Apo2L may be involved
in apoptosis of activated peripheral T cells [12], the bio-
logical role of this cytokine is not fully understood. The
existence of four receptors for Apo2L indicates unusually
complex regulation. The close linkage of the genes for
the four Apo2L receptors on human chromosome 8p21
suggests that they arise from recent gene duplication
events. To date, no other TNFR family members have
been mapped to chromosome 8p. It is notable that 8p21 is
a frequent site of chromosomal abberation in a variety of
human cancers [13]. DcR2 has a unique mRNA expres-
sion pattern compared with those of other Apo2L recep-
tors, suggesting that it has a distinct role. Our initial
characterization of DcR2 indicates that its truncated
death domain is not capable of signaling. Ectopic DcR2
expression provides protection against Apo2L-induced
apoptosis independently of the ICD of DcR2, suggesting
that this receptor can act as a decoy that sequesters the
ligand from its death-signaling receptors. Hence, DcR2
may fulfil an inhibitory role similar to that of DcR1,
perhaps in tissues that express high levels of DcR2, such
as fetal liver or adult testis. Nonetheless, because the
cytoplasmic sequence of DcR2 is distinct from that of
DR4 or DR5, it is conceivable that DcR2 may have some
signaling function of its own.
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Figure 2
Expression of DcR2 mRNA in human tissues. Poly(A)+ RNA blots
derived from human fetal and adult tissues (Clontech) were hybridized
to a 200 bp 32P-labeled DNA probe based on the 3′ untranslated
region of DcR2. PBL, peripheral blood leukocytes; Sm. int., small
intestine; Sk. mus., skeletal muscle.
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Figure 3
Interaction of DcR2 with Apo2L. (a) An immunoadhesin containing the
ECD of DcR2 (amino acids 1–212) fused to the hinge and Fc regions
of human IgG1 was generated as described [14]. DcR2, DR5 [4] or
TNFR1 [15] immunoadhesin (2.5 µ g) was incubated with 125I-labeled
soluble Apo2L [1] (1 ng, specific activity 10.7 µ Ci µ g–1) with or
without 1 µ g unlabeled Apo2L (1 h at 24°C). Complexes were
precipitated by protein A–Sepharose and resolved by electrophoresis
under reducing conditions. In the right-hand lane (control), 125I-Apo2L
was loaded directly. (b) Human HeLa S3 cells were incubated with
buffer or Apo2L (125 ng ml–1) in the presence of DcR2 or TNFR1
immunoadhesin (10 µ g ml–1) for 5 h, and analyzed for apoptosis by
annexin V binding as described [7]. The data are means ± s.e.m. of
triplicate determinations.
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Figure 4
DcR2 inhibits Apo2L activity. (a) HeLa S3
cells (106 per assay) were transfected by
electroporation with pRK5, or with pRK5
encoding DcR2 (clone 35663 or 35664), or
DR4 or DR5 (16 µ g), along with pRK5
encoding CD4 (4 µ g) as a transfection
marker. The level of apoptosis in CD4-
expressing cells was assessed 24 h later, by
analysis of annexin V binding [7]. (b) Human
293 cells (5 ×106 per assay) were transfected
by calcium-phosphate precipitation with
20 µ g pRK5, or pRK5 encoding either DcR2
clone, or DR4 or DR5. The cells were
analyzed 24 h later for activation of NF-κB
(arrow) by electrophoretic mobility shift assay
[7]. (c) Human 293 cells (106 per assay) were
transfected with 4 µ g pRK5, or pRK5
encoding either DcR2 clone, or a DcR2
mutant in which the intracellular domain
(amino acids 236–386) was deleted (∆ ICD),
along with 1 µ g pRK5 encoding green
fluorescent protein (GFP). After 24 h, the cells
were treated with Apo2L (1 µ g ml–1) for the
indicated time periods, stained with Hoechst
33342 dye (10 µ g ml–1), and double-positive
cells were scored for apoptotic morphology.
(d) HeLa S3 cells were transfected with the
indicated plasmids. After 15 h, cycloheximide
was added (10 µ g ml–1), and 1 h later, buffer
(white bar) or agonist anti-CD95 antibody
CH-11 (1 µ g ml–1; shaded bars) was added
for 5 h and apoptosis was analyzed as in (a).
The data in (a,c,d) are means ± s.e.m. of
triplicate determinations.
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